RCM Accretive Health

R1 RCM Appoints Vijay Kotte as Executive Vice President, Physician Services

R1 RCM Appoints Vijay Kotte as Executive Vice President, Physician Services

CHICAGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management (RCM) services to healthcare providers, today announced the appointment of Vijay Kotte as Executive Vice President of Physician Services.

Kotte will be responsible for R1’s physician-focused solutions, including growth, product development and strategic initiatives. Kotte joins R1 with more than 20 years of healthcare experience in consulting, operations, and developing new healthcare business ventures, including over 15 years of experience developing and managing value-based payment models for providers and payors.  Most recently, he was the Chief Value Officer for DaVita Medical Group with accountability for strategy, M&A, contracting, performance and operations. Prior to that, he was the Chief Financial Officer for DaVita Medical Group with responsibility for the finance function and oversight of joint ventures. Prior to DaVita, Kotte served as President and Chief Operating Officer of Medicare operations for Meridian Health Plan. Additionally, he previously served as President of the Midwest region for WellCare Health Plans, where he was responsible for operations, sales and long-term strategic planning.

“R1 has an extremely strong set of revenue cycle capabilities for the physician setting and I am very excited to join the team to further develop these capabilities and grow the company’s footprint,” said Kotte. “Physician groups face tremendous pressure to deliver high-quality care amid increasingly complex payment models, shrinking margins and rising consumerism. I look forward to leveraging R1’s capabilities to partner with physician groups to help them improve their patient experience while driving improved financial performance.”

“We are very pleased to have Vijay join the R1 team,” added Joe Flanagan, President and Chief Executive Officer of R1. “R1 has developed an industry-leading platform to serve healthcare providers across the continuum of care, and Vijay’s expertise will help us drive further growth in the physician setting, where we see an opportunity to deliver a highly differentiated solution relative to alternatives available in the market today.”

About R1 RCM

R1 RCM is a leading provider of technology-enabled RCM services which transform and solve revenue cycle performance challenges across hospitals, health systems and physician group practices. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: r1rcm.com.

Contact:

R1 RCM Inc.

Investor Relations:

Atif Rahim

312-324-5476

Media Relations:

Brenda Stewart

312-255-7786

EN
29/10/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Accretive Health

 PRESS RELEASE

TowerBrook and CD&R Complete Acquisition of R1 RCM

TowerBrook and CD&R Complete Acquisition of R1 RCM R1 RCM Becomes Privately Held Company; Joe Flanagan Reappointed as CEO MURRAY, Utah, Nov. 19, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (“R1”), a leader in automating revenue management for healthcare providers, today announced that investment funds affiliated with TowerBrook Capital Partners (“TowerBrook”) and Clayton, Dubilier & Rice (“CD&R”) have completed their previously announced acquisition of R1. On August 1, 2024, TowerBrook, CD&R and R1 announced that they had entered into a definitive merger agreement under which all outstanding ...

 PRESS RELEASE

R1 RCM Reports Third Quarter 2024 Results

R1 RCM Reports Third Quarter 2024 Results MURRAY, Utah, Nov. 05, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2024. Third Quarter 2024 Results: Revenue of $656.8 million, up $84.0 million or 14.7% compared to the same period last year.GAAP net loss of $19.9 million, compared to net income of $1.3 million in the same period last year.Adjusted EBITDA of $148...

 PRESS RELEASE

R1 RCM Reports Second Quarter 2024 Results

R1 RCM Reports Second Quarter 2024 Results MURRAY, Utah, Aug. 07, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended June 30, 2024. Second Quarter 2024 Results: Revenue of $627.9 million, up $67.2 million or 12.0% compared to the same period last year.GAAP net loss of $7.6 million, compared to net loss of $1.0 million in the same period las...

 PRESS RELEASE

R1 RCM to be Acquired by TowerBrook and CD&R for $8.9 Billion

R1 RCM to be Acquired by TowerBrook and CD&R for $8.9 Billion Stockholders to Receive $14.30 Per Share in Cash MURRAY, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has entered into a definitive agreement to be acquired by investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice (“CD&R”), in an all-cash transaction with an enterprise value of approxi...

 PRESS RELEASE

R1 RCM Special Committee Provides Update on Evaluation of Strategic Al...

R1 RCM Special Committee Provides Update on Evaluation of Strategic Alternatives Sets Final Bid Deadline of July 31, 2024 MURRAY, Utah, July 24, 2024 (GLOBE NEWSWIRE) -- The Special Committee of the R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”) Board of Directors, which comprises independent directors and was formed to evaluate strategic alternatives in response to the Schedule 13D/A filed by New Mountain Capital, L.L.C. (“New Mountain Capital”) with the Securities and Exchange Commission on February 26, 2024, today announced it has set a final deadline for interested parties to sub...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch